Latest news with #IQVIA
Business Wire
3 days ago
- Business
- Business Wire
IQVIA Announces Pricing of Senior Notes
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. ('IQVIA') (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the 'Issuer'), priced an offering of $2,000,000,000 in aggregate principal amount of senior notes due 2032 (the 'Notes'). The proceeds from the Notes offering will be used to repay existing borrowings under the Issuer's revolving credit facility and to pay fees and expenses related to the Notes offering, with any excess proceeds used for other general corporate purposes. The Notes will mature on June 1, 2032, unless earlier repurchased or redeemed in accordance with their terms. The Notes will bear interest at a rate of 6.250% per annum and will pay interest semi-annually in arrears on June 1 and December 1 of each year, beginning on December 1, 2025. The issuance of the Notes is expected to occur on or about June 4, 2025, subject to the satisfaction of customary closing conditions. This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solicitation or sale of the Notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. The Notes to be offered have not been registered under the Securities Act of 1933, as amended (the 'Securities Act'), or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in the United States in reliance on Rule 144A under the Securities Act and outside the United States only to non-U.S. investors pursuant to Regulation S under the Securities Act. Any offer of the Notes will be made only by means of a private offering memorandum. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI™, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using artificial intelligence responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 89,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. Forward Looking Statements Certain statements in this press release are forward-looking statements. These statements involve a number of risks, uncertainties and other factors, including the failure to consummate the Notes offering, and potential changes in market conditions that could cause actual results to differ materially. IQVIAFIN
Business Wire
3 days ago
- Business
- Business Wire
IQVIA Announces Offering of Senior Notes
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. ('IQVIA') (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the 'Issuer'), intends to raise $2,000,000,000 through an offering of senior notes due 2032 (the 'Notes'). The proceeds from the Notes offering will be used to repay existing borrowings under the Issuer's revolving credit facility and to pay fees and expenses related to the Notes offering, with any excess proceeds used for other general corporate purposes. The consummation of the Notes offering is subject to market and other customary conditions. This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solicitation or sale of the Notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. The Notes to be offered have not been registered under the Securities Act of 1933, as amended (the 'Securities Act'), or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in the United States in reliance on Rule 144A under the Securities Act and outside the United States only to non-U.S. investors pursuant to Regulation S under the Securities Act. Any offer of the Notes will be made only by means of a private offering memorandum. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI™, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using artificial intelligence responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 89,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. Forward Looking Statements Certain statements in this press release are forward-looking statements. These statements involve a number of risks, uncertainties and other factors, including the failure to consummate the Notes offering, and potential changes in market conditions that could cause actual results to differ materially.
Korea Herald
28-05-2025
- Business
- Korea Herald
Celltrion's Remsima SC hits fivefold growth in Europe
South Korean biopharmaceutical firm Celltrion announced Wednesday that the market share of Remsima SC, the subcutaneous formulation of the autoimmune disease treatment infliximab, has quintupled across Europe over just four years. According to the company, citing global pharmaceutical market research firm IQVIA, Remsima SC captured a 22 percent market share as of last year, surging from 4 percent in 2021 following its debut in 2020. When combined with the share of Remsima, the intravenous version, Celltrion's Remsima product line commanded a 71 percent market share in Europe. Celltrion noted that Remsima SC's success in Europe bodes well for the US market, given that its recent inclusion of Zymfentra — another brand name for Remsima SC in the US — in major US insurance formularies is expected to drive accelerated adoption. Celltrion's other autoimmune treatments are also making significant inroads in Europe. Yuflyma, its adalimumab-aaty biosimilar, secured a 21 percent market share last year. Meanwhile, its ustekinumab biosimilar, Steqeyma, launched in Europe in October, captured more than 2 percent market share within just a few months. 'Remsima SC's growing presence in Europe can be attributed to its convenience, treatment efficacy and tailored sales strategies from our local subsidiaries,' a Celltrion official said. 'With our existing products leading prescriptions in Europe, we plan to continue our growth through the launch of new biosimilars during the remainder of the year.'
Business Standard
26-05-2025
- Business
- Business Standard
Zydus Life gets USFDA nod for Isotretinoin capsules
Zydus Lifesciences announced that it has received a final approval for Isotretinoin capsules from US Food and Drug Administration (USFDA). The approved drug is the generic equivalent of the reference listed drug Absorica capsules, available in 10 mg, 20 mg, 25 mg, 30 mg, 35 mg, and 40 mg strengths. Isotretinoin capsules are indicated to treat severe, disfiguring nodular acne. The product will be manufactured at the Groups facility in Moraiya, Ahmedabad. According to IQVIA MAT 2025, Isotretinoin capsules had annual sales of $115.4 million in the United States. As of 31st March 2025, the group now has received a total of 427 approvals and has so far filed 492 ANDAs since the commencement of the filing process in FY 2003-04. Zydus Lifesciences is a global life sciences company engaged in the discovery, development, manufacturing, and marketing of a wide range of healthcare therapies. The companys consolidated net profit fell 1% to Rs 1,170.90 crore despite of 17.2% increase in net sales to Rs 6290.20 crore in Q4 FY25 over Q4 FY24. The counter rose 0.45% to settle at Rs 908 on Friday, 23 May 2025.
Korea Herald
22-05-2025
- Business
- Korea Herald
Celltrion's Steqeyma gains wider insurance coverage in US
South Korean biopharmaceutical firm Celltrion announced Thursday that it has signed a second major deal with one of the top five pharmacy benefit managers in the US, securing private insurance coverage for its autoimmune disease treatment, Steqeyma (ustekinumab). Starting July 1, Steqeyma will be eligible for reimbursement through the newly secured PBM, significantly broadening patient access. This agreement follows an earlier deal finalized on April 3 with one of the top three PBMs in the US, giving Steqeyma a foothold in both public and private insurance formularies. With these two contracts, Celltrion now covers nearly 30 percent of the US pharmaceutical insurance market, which is an impressive milestone achieved within a month of the company's US launch. Celltrion's prior success with its other autoimmune treatments, such as Zymfentra and Yuflyma, has helped build trust among US health care providers. The company plans to leverage its expanded product portfolio for bundled marketing strategies, enhancing its competitiveness in the US market. According to pharmaceutical market research firm IQVIA, the global market for ustekinumab reached $21.6 billion in 2024, with the US accounting for nearly 77 percent. Celltrion aims to further strengthen collaboration with doctors, insurers and patient groups to ensure broad access to Steqeyma.
